{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:00:58Z","timestamp":1784293258678,"version":"3.55.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Apoptosis is an essential characteristic of cancer and its dysregular promotes tumor growth, clonal evolution, and treatment resistance. B-cell lymphoma-2 (BCL-2) protein family members are key to the intrinsic, mitochondrial apoptotic pathway. The inhibition of the BCL-2 family pro-survival proteins, which are frequently overexpressed in B-cell malignancies and pose a fundamental carcinogenic mechanism has been proposed as a promising therapeutic option, with venetoclax (ABT-199) being the first FDA-approved BCL-2 inhibitor. Unfortunately, although BCL-2 inhibition has shown remarkable results in a range of B-cell lymphoid cancers as well as acute myeloid leukemia (AML), the development of resistance significantly reduces response rates in specific tumor subtypes. In this article, we explain the role of BCL-2 family proteins in apoptosis and their mechanism of action that justifies their inhibition as a potential treatment target in B-cell malignancies, including chronic lymphocytic leukemia, multiple myeloma, B-cell lymphomas, but also AML. We further analyze the tumor characteristics that result in the development of intrinsic or inherited resistance to BCL-2 inhibitors. Finally, we focus on the biomarkers that can be used to predict responses to treatment in the name of personalized medicine, with the goal of exploring alternative strategies to overcome resistance.<\/jats:p>","DOI":"10.3389\/fonc.2024.1501950","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:38:24Z","timestamp":1737448704000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies"],"prefix":"10.3389","volume":"14","author":[{"given":"Mariam","family":"Markouli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria N.","family":"Pagoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Diamantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14010087","article-title":"FDA-approved drugs for hematological Malignancies\u2014The last decade review","volume":"14","author":"Sochacka-\u0107wik\u0142a","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14143330","article-title":"Updates in the use of BCL-2-family small molecule inhibitors for the treatment of relapsed\/refractory multiple myeloma","volume":"14","author":"Parrondo","year":"2022","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2019.00697\/FULL","article-title":"Efficacy and safety of BcL-2 inhibitor venetoclax in hematological Malignancy: A systematic review and meta-analysis of clinical trials","volume":"10","author":"Li","year":"2019","journal-title":"Front Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4155\/BIO-2021-0207","article-title":"LC-MS\/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction","volume":"14","author":"Reddy","year":"2022","journal-title":"Bioanalysis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41418-022-01082-0","article-title":"When cell death goes wrong: inflammatory outcomes of failed apoptosis and mitotic cell death","volume":"30","author":"Bock","year":"2022","journal-title":"Cell Death Differ"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge","year":"2015","journal-title":"Cell Death Differ"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-018-0608-2\/TABLES\/2","article-title":"BCL-2 as therapeutic target for hematological Malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/J.TIBS.2013.12.006","article-title":"Many players in BCL-2 family affairs","volume":"39","author":"Moldoveanu","year":"2014","journal-title":"Trends Biochem Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/NRD2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat Rev Drug Discovery"},{"key":"B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/NRM2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/EMBOJ.2011.307","article-title":"Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases","volume":"30","author":"Strasser","year":"2011","journal-title":"EMBO J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell Malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","article-title":"Found in translation: how preclinical research is guiding the clinical development of the BCL-2-selective inhibitor venetoclax","volume":"7","author":"Leverson","year":"2017","journal-title":"Cancer Discovery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2012.08.008","article-title":"The pantheon of the fallen: Why are there so many forms of cell death","volume":"22","author":"Green","year":"2012","journal-title":"Trends Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165914","article-title":"A chemo-free bridge-to-transplant strategy with venetoclax and azacitidine for NPM1-mutated acute myeloid leukemia in molecular failure","volume":"140","author":"Sartor","year":"2022","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.clml.2022.07.013","article-title":"SOHO state of the art updates and next questions | Mechanisms of resistance to BCL2 inhibitor therapy in chronic lymphocytic leukemia and potential future therapeutic directions","volume":"22","author":"Bennett","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/CDD.2017.159","article-title":"BCL2 and miR-15\/16: from gene discovery to treatment","volume":"25","author":"Pekarsky","year":"2018","journal-title":"Cell Death Differ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2013-10-534073","article-title":"Stimulation of the B-cell receptor activates the JAK2\/STAT3 signaling pathway in chronic lymphocytic leukemia cells","volume":"123","author":"Rozovski","year":"2014","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA050995","article-title":"A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403954","article-title":"Translocation t(14;18) and gain of chromosome 18\/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Galteland","year":"2005","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2018.00636\/BIBTEX","article-title":"Targeting the Bcl-2 family in B cell lymphoma","volume":"9","author":"Adams","year":"2019","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.777587\/BIBTEX","article-title":"Notch2 increases the resistance to venetoclax-induced apoptosis in chronic lymphocytic leukemia B cells by inducing mcl-1","volume":"11","author":"Fiorcari","year":"2022","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2018","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/J.SEMCANCER.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell Malignancies: insight into disease biology and new targeted therapies","volume":"24","author":"Burger","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2019000367","article-title":"Clonal dynamics in chronic lymphocytic leukemia","volume":"3","author":"Gutierrez","year":"2019","journal-title":"Blood Adv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2015.124560","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1119\/42809\/AM\/ACQUISITION-OF-THE-RECURRENT-GLY101VAL-MUTATION-IN","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discovery"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/J.CCELL.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid Malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.19314","article-title":"Venetoclax resistance in acute myeloid leukaemia\u2014Clinical and biological insights","volume":"204","author":"Nachmias","year":"2024","journal-title":"Br J Haematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13122974","article-title":"Potential biomarkers for treatment response to the BCL-2 inhibitor venetoclax: state of the art and future directions","volume":"13","author":"Salah","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/PNAS.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/435983","article-title":"Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go","volume":"2014","author":"Puiggros","year":"2014","journal-title":"BioMed Res Int"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/HAEMATOL.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/NRI3565","article-title":"NOD proteins: regulators of inflammation in health and disease","volume":"14","author":"Philpott","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1563694","article-title":"MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells","volume":"60","author":"Wang","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in understanding the mechanisms of resistance to BCL-2 inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-018-05815-Z","article-title":"Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity","volume":"9","author":"Soderquist","year":"2018","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/BLOOD-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1291920","article-title":"Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review","volume":"14","author":"Cao","year":"2023","journal-title":"Front Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"key":"B57","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/NATURE08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/BLOOD.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/J.BLRE.2020.100672","article-title":"Targeting MCL-1 in hematologic Malignancies: Rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-1122-x","article-title":"Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma","volume":"39","author":"Dengler","year":"2019","journal-title":"Oncogene"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discovery"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4322","article-title":"Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma","volume":"67","author":"Gomez-Bougie","year":"2007","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/LEU.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2005-01-0320","article-title":"Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma","volume":"106","author":"Raje","year":"2005","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/BJC.2017.432","article-title":"Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo","volume":"118","author":"Zhou","year":"2018","journal-title":"Br J Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.21203\/RS.3.RS-3015916\/V1","article-title":"Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia","volume":"4","author":"Bouligny","year":"2023","journal-title":"Res Sq"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/S12935-020-01614-Z","article-title":"Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic Malignancies","volume":"20","author":"Yue","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.287","article-title":"MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1\/BIM complex","volume":"26","author":"Konopleva","year":"2012","journal-title":"Leukemia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.659","article-title":"Ras\/raf\/MEK\/ERK and PI3K\/PTEN\/akt\/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid Malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/BLOOD-2018-08-872465","article-title":"Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","author":"Bojarczuk","year":"2019","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2019000844","article-title":"Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models","volume":"4","author":"Tarantelli","year":"2020","journal-title":"Blood Adv"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.382","article-title":"Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.4857","article-title":"Cyclin E\/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics","volume":"6","author":"Choudhary","year":"2015","journal-title":"Oncotarget"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2042689","article-title":"Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells","volume":"63","author":"Valdez","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/J.BCP.2022.115283","article-title":"Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia","volume":"205","author":"Hege Hurrish","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3009\/658570\/P\/STALLING-THE-ENGINE-OF-RESISTANCE-TARGETING-CANCER","article-title":"Stalling the engine of resistance: Targeting cancer metabolism to overcome therapeutic resistance","volume":"73","author":"Butler","year":"2013","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2011-09-377846","article-title":"Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy","volume":"119","author":"McBrayer","year":"2012","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.179101","article-title":"Akt requires glucose metabolism to suppress Puma expression and prevent apoptosis of leukemic T cells","volume":"286","author":"Coloff","year":"2011","journal-title":"J Biol Chem"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.327","article-title":"Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis","volume":"26","author":"Meynet","year":"2012","journal-title":"Leukemia"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.464","article-title":"Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax","volume":"35","author":"Bajpai","year":"2016","journal-title":"Oncogene"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2023019706\/2209534\/BLOOD.2023019706.PDF","article-title":"Sonrotoclax overcomes BCL2 G101V mutation\u2013induced venetoclax resistance in preclinical models of hematologic Malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2020.564108","article-title":"Clinical review: navitoclax as a pro-apoptotic and anti-fibrotic agent","volume":"11","author":"Mohamad Anuar","year":"2020","journal-title":"Front Pharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/NM.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/ACEL.13142","article-title":"Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity","volume":"19","author":"Gonz\u00e1lez-Gualda","year":"2020","journal-title":"Aging Cell"},{"key":"B90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/CE.S42568","article-title":"An evidence-based review of obatoclax mesylate in the treatment of hematological Malignancies","volume":"8","author":"Goard","year":"2013","journal-title":"Core Evid"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007708","article-title":"Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes","volume":"6","author":"Hyak","year":"2022","journal-title":"Blood Adv"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1501950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:38:29Z","timestamp":1737448709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1501950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":91,"alternative-id":["10.3389\/fonc.2024.1501950"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1501950","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"article-number":"1501950"}}